Polycythemia vera

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:729OMIM:263300D45
Who is this for?
Show terms as
2FDA treatments20Active trials43Specialists8Treatment centers3Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Polycythemia Vera is treated with 1 medication in our database, including BESREMi. 1 of these has manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by PharmaEssentia. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Polycythemia Vera treatment below.

Also known as:

Clinical phenotype terms— hover any for plain English:

PolycythemiaHP:0001901Acute leukemiaHP:0002488MyelofibrosisHP:0011974
Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

10 events
Jun 2026A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)

Ono Pharmaceutical Co. Ltd — PHASE3

TrialNOT YET RECRUITING
Feb 2026A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV

Duan Minghui — NA

TrialNOT YET RECRUITING
Jan 2026Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter Study

Federico II University

TrialNOT YET RECRUITING
Jan 2026Potential Biological and Physiological Determinants for Exercice in Patients With Polycythemia Vera

Hospices Civils de Lyon — NA

TrialNOT YET RECRUITING
Sep 2025MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

MPN Research Foundation — NA

TrialRECRUITING
Sep 2025Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera

Chengdu Zenitar Biomedical Technology Co., Ltd — PHASE2

TrialRECRUITING
Aug 2025A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

Disc Medicine, Inc — PHASE2

TrialRECRUITING
Jun 2025Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)

BeBetter Med Inc — PHASE1

TrialNOT YET RECRUITING
May 2025Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History

Fondazione Policlinico Universitario Agostino Gemelli IRCCS — NA

TrialNOT YET RECRUITING
Dec 2024Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly

iOMEDICO AG

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

2 available

JAKAFI

RUXOLITINIB· Incyte Corporation

treatment of polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea

Besremi

ropeginterferon alfa-2b-njft· PharmaEssentia■ Boxed WarningOrphan Drug

Treatment of adults with polycythemia vera

Clinical Trials

20 recruitingView all trials with filters →
Phase 37 trials
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Phase 3
Actively Recruiting
PI: Keita Kirito, MD (University of Yamanashi Hospital) · Sites: Toon-shi, Ehime; Tsu, Mie-ken +4 more · Age: 2099 yrs
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
Phase 3
Active
· Sites: Mobile, Alabama; Glendale, Arizona +182 more · Age: 1899 yrs
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Phase 3
Active
PI: Bristol-Myers Squibb (Bristol-Myers Squibb) · Sites: Los Angeles, California; Orlando, Florida +183 more · Age: 1899 yrs
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
Phase 3
Actively Recruiting
PI: Claire Harrison (Acting on behalf of the Sponsor (UK), Guy's Hospit) · Sites: Aberdeen; Bath +45 more · Age: 1899 yrs
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
Phase 3
Active
· Sites: Covington, Louisiana · Age: 1899 yrs
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
Phase 3
Actively Recruiting
· Sites: Birmingham, Alabama; Redlands, California +88 more · Age: 1899 yrs
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
Phase 3
Active
PI: Ole Zagrijtschuk, MD, PhD (PharmaEssentia Corporation) · Sites: Jacksonville, Florida; Fort Wayne, Indiana +21 more · Age: 1899 yrs
Phase 25 trials
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
Phase 2
Active
PI: Steffen Koschmieder, Prof. Dr. (RWTH University Hospital MK4) · Sites: Mannheim, Baden-Wurttemberg; Ulm, Baden-Wurttemberg +21 more · Age: 1899 yrs
Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
Phase 2
Actively Recruiting
PI: Lei Zhang, MD (Institute of Hematology & Blood Diseases Hospital,) · Sites: Tianjin · Age: 1899 yrs
Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Phase 2
Actively Recruiting
PI: Lei Zhang, Doctor (Institute of Hematology & Blood Diseases Hospital,) · Sites: Tianjin · Age: 1899 yrs
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
Phase 2
Active
PI: Jingjing Zhang (PharmaEssentia) · Sites: Beijing; Changsha +12 more · Age: 1899 yrs
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Phase 2
Actively Recruiting
PI: Will Savage, MD PhD (Disc Medicine) · Sites: Phoenix, Arizona; Los Angeles, California +12 more · Age: 1899 yrs
Phase 11 trial
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
Phase 1
Actively Recruiting
· Sites: Zhengzhou, Henan; Wuhan, Hubei +4 more · Age: 1899 yrs
N/A1 trial
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
N/A
Actively Recruiting
PI: Raajit Rampal, MD, PhD (Memorial Sloan Kettering Cancer Center) · Sites: Chicago, Illinois; New York, New York · Age: 1899 yrs
Other5 trials
Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera
Active
PI: Novartis Pharmaceuticals (Novartis Pharmaceuticals) · Sites: Alessandria, AL; Ancona, AN +33 more · Age: 1899 yrs
Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)
Active
PI: TIZIANO BARBUI, MD (FROM- Fondazione per la Ricerca Ospedale di Bergam) · Sites: Bergamo, Lombardy; Milan, Lombardy +35 more · Age: 18100 yrs
Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly
Actively Recruiting
PI: Eyck von der Heyde, Dr. (Onkologische Schwerpunktpraxis) · Sites: Hanover, Lower Saxony · Age: 1899 yrs
LOW-PV Continuation
Actively Recruiting
PI: TIZIANO BARBUI, MD (FROM- Fondazione per la Ricerca Ospedale di Bergam) · Sites: Pavia, Lombardy; Verona, Veneto +11 more · Age: 18100 yrs
Effect of Phlebotomy on Heartrate in Polycythemia Patients
Actively Recruiting
PI: Jaap Jan Zwaginga, MD, PhD (LUMC) · Sites: Leiden, South Holland · Age: 1899 yrs

Specialists

Showing 25 of 43View all specialists →
JK
Jean-Jacques Kiladjian
Specialist
PI on 1 active trial3 Polycythemia vera publications
JZ
Jingjing Zhang
PHILADELPHIA, PA
Specialist
PI on 1 active trial1393 Polycythemia vera publications
AY
Abdulraheem Yacoub
WESTWOOD, KS
Specialist
2 Polycythemia vera publications
BR
Brandi N Reeves
DOTHAN, AK
Specialist
2 Polycythemia vera publications
JP
Josef T Prchal
SALT LAKE CITY, UT
Specialist
2 Polycythemia vera publications
AM
Adam J Mead
Specialist
2 Polycythemia vera publications
MM
Mary Frances McMullin
MONROE, MI
Specialist
2 Polycythemia vera publications
AD
Amylou C Dueck
Specialist
2 Polycythemia vera publications
LM
Lucia Masarova
HOUSTON, TX
Specialist
2 Polycythemia vera publications
JM
John Mascarenhas
NEW YORK, NY
Specialist
3 Polycythemia vera publications
MK
Marina Kremyanskaya
NEW YORK, NY
Specialist
4 Polycythemia vera publications
TB
Tiziano Barbui
Specialist
4 Polycythemia vera publications
AV
Alessandro M Vannucchi
Specialist
3 Polycythemia vera publications
RM
Ruben A Mesa
CHARLOTTE, NC
Specialist
3 Polycythemia vera publications
RH
Ronald Hoffman
Specialist
3 Polycythemia vera publications
CH
Claire Harrison
Specialist
PI on 1 active trial24 Polycythemia vera publications
GM
Gabriela Hobbs, MD
BOSTON, MA
Specialist
PI on 4 active trials1 Polycythemia vera publication
JM
Jean-Jacques Kiladjian, MD
Specialist
PI on 1 active trial
AP
Anand A Patel
Specialist
PI on 1 active trial256 Polycythemia vera publications
SS
Simran Singh
Birmingham, Alabama
Specialist

Rare Disease Specialist

PI on 3 active trials428 Polycythemia vera publications
ZP
ZhenYa Hong, Ph.D
Specialist
PI on 1 active trial
LP
Lesley A Anderson, PhD
Specialist
PI on 1 active trial
SP
Srdan Verstovsek, MD, PhD
HOUSTON, TX
Specialist
PI on 3 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

2 resources
JAKAFI(RUXOLITINIB)Incyte Corporation
Besremi(ropeginterferon alfa-2b-njft)PharmaEssentia

1 travel grant are also available for Polycythemia vera patients — see Travel Grants below ↓

Travel Grants

1 grants

Susan Lang Pay-It Forward Patient Travel Assistance Programs

Leukemia & Lymphoma Society

Assistance is available for patients diagnosed with Myeloproliferative Neoplasms (MPNs) to cover costs for medication co-pays, travel to cancer centers, and health insurance premiums. Eligibility generally requires a valid diagnosis of an MPN, such as myelofibrosis or polycythemia vera, and vary by individual program provider.

Apply ↗

Community

Open Polycythemia veraForum →

No community posts yet. Be the first to share your experience with Polycythemia vera.

Start the conversation →

Latest news about Polycythemia vera

1 articles
Clinical trialUNITERAREApr 3, 2026
New Recruiting Trial: A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Prelude Therapeutics is testing a new drug called PRT12396 in people with certain blood cancers called myeloproliferative neoplasms. This is an early-stage stud
See all news about Polycythemia vera

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Polycythemia vera

What is Polycythemia vera?

Polycythemia Vera is treated with 1 medication in our database, including BESREMi. 1 of these has manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by PharmaEssentia. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Polycythemia Vera treatment below.

Are there clinical trials for Polycythemia vera?

Yes — 20 recruiting clinical trials are currently listed for Polycythemia vera on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Polycythemia vera?

25 specialists and care centers treating Polycythemia vera are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Polycythemia vera?

1 FDA-approved treatment and 1 patient support program are currently tracked on UniteRare for Polycythemia vera. See the treatments and support programs sections for copay assistance, eligibility, and contact details.